Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients - Trial NCT06353828
Access comprehensive clinical trial information for NCT06353828 through Pure Global AI's free database. This Phase 2 trial is sponsored by CannaMore Biotechs and is currently Recruitment Completed. The study focuses on Ulcerative Colitis. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
CannaMore Biotechs
Timeline & Enrollment
Phase 2
Mar 01, 2023
Apr 01, 2025
Primary Outcome
Change from baseline in Full Mayo Score
Summary
Ulcerative proctitis can lead to considerable morbidity, and the available treatment options
 are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses
 potent immunomodulatory and anti-inflammatory properties as described in both acute and
 chronic animal models of inflammation, including IBD models.
 
 Based on positive safety and initial efficacy profiles of CBD found in IBD animal and
 clinical studies, the main aim of this study is to evaluate the safety, tolerability and
 efficacy of a novel enema formulation of CBD for the treatment of active ulcerative
 proctitis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06353828
Non-Device Trial